葵花药业 (002737)

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

ASZ

Tags

CSI Dividend IndexGuoxin Value IndexInfant and Child ConceptVitaminsHepatitis ConceptHigh-Dividend StocksShenzhen ConnectPharma & BiotechChinese Med. IIStable Growth IndexSZSE Medicine Equal Weight IndexShenzhen A-Share Pharmaceutical IndexCS High Dividend Yield IndexCSI All-share Pharmaceutical Sector IndexSmart Select High Dividend IndexSZSE 700 IndexSSE 700 Growth IndexZhongchuang Growth IndexSZSE 1000 IndexCSI 1000 Growth IndexSZSE Component Index ReturnExcellent Performance Strategy IndexSZSE Performance IndexSME Board Value IndexZhongchuang Value IndexInfluenza/MaskOptimized Fertility (Three-child)FTSE Russell ConceptHuijin ConceptInsurance Heavy HoldingsFull Circulation SharesSME Board Composite IndexSZSE Selected IndexCNI 2000 IndexSME Board Innovation IndexManufacturing IndexSZSE Pharmaceutical IndexDividend Quality IndexCS Pharmaceutical TI IndexCSI 1000 IndexDividend 100 IndexSZSE Component Pharmaceutical IndexCSI All-share Pharmaceutical IndexSME Board Low Volatility IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexHigh Dividend Yield Strategy IndexSME Board Dividend IndexPharmaceutical 50 IndexZhongchuang Low Volatility IndexPharmaceutical 50 Strategy IndexCSI 1000 Growth Innovation IndexCICC 300 IndexSZSE Dividend 50 IndexZhongchuang 400 IndexCR New Momentum IndexDividend 200 IndexCSI 1000 Value IndexCSI 1000 Value Stable IndexPerformance IndexHeilongjiang

K-Line Chart

No K-line data available

Company NameKuihua Pharmaceutical Group Co., Ltd.
Listing Date2014-12-30
Issue Price36.53RMB
Registered Capital5840010k RMB
Legal RepresentativeGuan Yuxiu
Registered AddressNo. 18 Donghu Road, Yingbin Road Concentration Zone, Harbin High-Tech Industrial Development Zone, Heilongjiang Province
IndustryTraditional Chinese Medicine II
Main BusinessResearch and development, production, and sales of various traditional Chinese medicines and chemical drugs (including biological drugs). The company and its subsidiaries collectively possess 722 varieties of "Zhun"-licensed drugs across 15 dosage forms, including tablets, pills, powders, suppositories, capsules, mixtures, granules, syrups, ointments, extracts, sprays, etc. This includes 1 national protected traditional Chinese medicine variety, 12 exclusive varieties, 402 drugs listed in the national medical insurance catalog, and 181 drugs listed in the national essential drugs catalog.
Company ProfileKuihua Pharmaceutical Group is a large private pharmaceutical enterprise group primarily focused on traditional Chinese medicines, supplemented by chemical drugs, biological drugs, and health supplement products. It integrates drug manufacturing, marketing, and scientific research. It is recognized as one of the "Top 100 Enterprises in China's Pharmaceutical Manufacturing Industry," "Top 50 Fastest-Growing Enterprises in China's Pharmaceutical Industry," and "Top 10 Standardized Planting Bases for High-Quality Genuine Chinese Medicinal Materials in China." In terms of technological R&D, Kuihua has successfully developed nationally renowned traditional Chinese medicine products represented by Hugan Pian (Liver Protection Tablets) and Weikangling Capsules, making outstanding contributions to the development of China's traditional Chinese medicine industry.

Stock Details

1. Key Indicators

  • Total Shares(W): 58400.00
  • Circulating A-Shares(W): 58400.00
  • Earnings Per Share(RMB): -0.0600
  • Net Assets Per Share(RMB): 6.9394
  • Operating Revenue(W RMB): 168398.40
  • Total Profit(W RMB): -623.48
  • Net Profit Attributable to Parent(W RMB): -3353.87
  • Net Profit Growth Rate(%): -105.72
  • Weighted Return on Equity(%): -0.7700
  • Operating Cash Flow Per Share(RMB): 0.3770
  • Undistributed Profit Per Share(RMB): 3.8393
  • Capital Reserve Per Share(RMB): 1.5727

2. Main Business

The main business covers:

  • Research, manufacturing and marketing of pharmaceuticals
  • Research, manufacturing and marketing of health and wellness products

3. Company Basic Information

  • Company Name: Sunflower Pharmaceutical Group Co., Ltd.
  • Listing Date: 2014-12-30
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 18 Donghu Road, Yingbin Road Concentration Zone, Harbin High-tech Industrial Development Zone, Heilongjiang Province, China
  • Website: www.kuihuayaoye.com
  • Company Profile: The Company was established by the overall change of Sunflower Pharmaceutical Group Co., Ltd. into a joint stock company. On August 2, 2009, Sunflower Limited held a shareholders' meeting, and with the unanimous consent of all shareholders, Sunflower Limited used the net assets of RMB 95,297,582.57 as of December 31, 2008, audited by Zhongrui Yuehua's "Audit Report" (Zhongrui Yuehua Audit No. [2009] 05349), distributed a cash dividend of RMB 7,647,824.33, and then converted into 86.8 million shares at a ratio of 1:0.99, with the remaining RMB 849,758.24 included in capital reserve. On August 17, 2009, Zhongrui Yuehua issued the "Capital Verification Report" (Zhongrui Yuehua Verification No. (2009) 109), verifying the capital contribution for this overall change to establish a joint stock company. On September 1, 2009, the Company obtained the "Business License" (Registration No. 230199100055264).

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Sunflower Group Co., Ltd. General Legal Person 26520.00 45.41
2 Heilongjiang Jinkui Investment Co., Ltd. General Legal Person 2400.00 4.11
3 E Fund CSI Dividend ETF Fund 340.08 0.58
4 Hong Kong Securities Clearing Company Ltd. Northbound Capital 284.12 0.49
5 China Merchants CSI Dividend ETF Fund 283.82 0.49
6 Southern CSI 1000 ETF Fund 267.57 0.46
7 Xiangcai Pharmaceutical Health Hybrid Securities Investment Fund Class A Fund 16.87 0.03
8 Hui'an Asset Rotation Flexible Allocation Hybrid Securities Investment Fund Class A Fund 3.35 0.01

5. Concept Sectors

  • Infant & Child Concept
  • Vitamin
  • Hepatitis Concept
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • High Dividend Stocks
  • SME 300 Index
  • CSI Dividend Index

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information